CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People

Area of Science:

• Pharmacogenetics
• Psychopharmacology
• Clinical Pharmacy

Background:

• Risperidone pharmacokinetics and efficacy are influenced by CYP2D6 genetic variations.
• Existing dosing recommendations for risperidone primarily focus on white populations.
• Tailoring risperidone dosage based on CYP2D6 genotype is crucial for optimizing treatment outcomes.

Purpose of the Study:

• To establish risperidone dose recommendations for Asian individuals using CYP2D6 genotype information.
• To investigate the impact of CYP2D6 polymorphism on risperidone pharmacokinetics in Chinese schizophrenia patients.
• To compare risperidone dose adjustments between Asian and white populations.

Main Methods:

• Investigated CYP2D6 genotype-pharmacokinetic relationships in Chinese schizophrenia patients.
• Conducted a meta-analysis of published studies on risperidone pharmacokinetics and CYP2D6 genotype.
• Calculated genotype-based risperidone dose adjustments for white and Asian populations.

Main Results:

• Significant pharmacokinetic differences were observed between CYP2D6 metabolizer groups.
• Meta-analysis revealed significant variations in risperidone concentrations across different CYP2D6 phenotypes.
• Asian poor metabolizers require a 26% risperidone dose reduction, while ultrarapid metabolizers need a 30% increase.

Conclusions:

• Genotype-guided risperidone dosing is essential for personalized medicine in Asian populations.
• Recommended risperidone dose adjustments differ between Asian and white individuals based on CYP2D6 genotype.
• Further research is needed to validate and expand these pharmacogenetic dosing recommendations for Asians.